迪哲医药-U
(688192)
| 流通市值：333.31亿 | | | 总市值：373.73亿 |
| 流通股本：4.10亿 | | | 总股本：4.59亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 159,641,464.34 | 359,900,621.06 | 338,451,000 | 203,550,120 |
| 营业收入 | 159,641,464.34 | 359,900,621.06 | 338,451,000 | 203,550,120 |
| 二、营业总成本 | 382,021,501.25 | 1,356,850,887.84 | 1,031,763,876.35 | 673,944,868.12 |
| 营业成本 | 7,071,641.67 | 9,316,308.61 | 7,696,980.46 | 4,770,353.28 |
| 税金及附加 | 379,400.3 | 2,040,790.21 | 1,547,964.07 | 1,087,804.42 |
| 销售费用 | 123,552,561.58 | 445,331,190.18 | 322,538,660.25 | 203,389,409.57 |
| 管理费用 | 32,502,067.44 | 153,445,761.53 | 116,388,159.08 | 72,286,122.04 |
| 研发费用 | 210,333,356.42 | 723,687,401.43 | 567,728,545.76 | 382,770,088.88 |
| 财务费用 | 8,182,473.84 | 23,029,435.88 | 15,863,566.73 | 9,641,089.93 |
| 其中:利息费用 | 8,495,528.4 | 22,754,524.23 | 15,440,908.96 | 9,472,184.8 |
| 其中:利息收入 | -562,288.47 | 2,242,276.01 | 1,635,226.42 | 1,079,091.98 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,607,839.77 | 14,450,692.6 | 10,928,993.99 | 7,370,318.18 |
| 信用减值损失(新) | -211,372.94 | 118,259.17 | -273,021.77 | -378,741.77 |
| 其他收益 | 25,242,840.17 | 41,080,270.13 | 31,609,998.05 | 31,106,335.37 |
| 四、营业利润 | -193,740,729.91 | -941,301,044.88 | -651,046,906.08 | -432,296,836.34 |
| 加:营业外收入 | - | 1,652,961 | 1,402,961 | - |
| 减:营业外支出 | - | 3,253.32 | - | - |
| 五、利润总额 | -193,740,729.91 | -939,651,337.2 | -649,643,945.08 | -432,296,836.34 |
| 减:所得税费用 | - | 3,851.5 | 3,502.98 | 1,340.34 |
| 六、净利润 | -193,740,729.91 | -939,655,188.7 | -649,647,448.06 | -432,298,176.68 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -193,740,729.91 | -939,655,188.7 | -649,647,448.06 | -432,298,176.68 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -192,513,348.95 | -845,956,285.93 | -558,460,529.94 | -344,750,887.77 |
| 少数股东损益 | -1,227,380.96 | -93,698,902.77 | -91,186,918.12 | -87,547,288.91 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.46 | -2.04 | -1.35 | -0.83 |
| (二)稀释每股收益 | -0.46 | -2.04 | -1.35 | -0.83 |
| 九、综合收益总额 | -193,740,729.91 | -939,655,188.7 | -649,647,448.06 | -432,298,176.68 |
| 归属于母公司股东的综合收益总额 | -192,513,348.95 | -845,956,285.93 | -558,460,529.94 | -344,750,887.77 |
| 归属于少数股东的综合收益总额 | -1,227,380.96 | -93,698,902.77 | -91,186,918.12 | -87,547,288.91 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |